Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Cash Flow-to-Debt Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of $118.45 Million could theoretically repay 0% of its total liabilities ($2.78 Billion) in one year. See AMRX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Amneal Pharmaceuticals, Inc. Class A Common Stock Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Amneal Pharmaceuticals, Inc. Class A Common Stock across 10 annual periods. Also explore net asset growth rate of Amneal Pharmaceuticals, Inc. Class A Com to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
Year-by-year debt coverage analysis for Amneal Pharmaceuticals, Inc. Class A Common Stock. For market capitalisation and broader financial context, see Amneal Pharmaceuticals, Inc. Class A Com stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.08x | $295.10 Million | $3.55 Billion | ▼ -16.9% |
| 2023 | 0.10x | $345.58 Million | $3.45 Billion | ▲ +452.0% |
| 2022 | 0.02x | $65.10 Million | $3.59 Billion | ▼ -73.2% |
| 2021 | 0.07x | $241.82 Million | $3.57 Billion | ▼ -34.6% |
| 2020 | 0.10x | $379.00 Million | $3.66 Billion | ▲ +20052.3% |
| 2019 | 0.00x | $1.71 Million | $3.32 Billion | ▼ -99.3% |
| 2018 | 0.07x | $250.23 Million | $3.46 Billion | ▼ -46.9% |
| 2017 | 0.14x | $234.19 Million | $1.72 Billion | ▲ +65.3% |
| 2016 | 0.08x | $115.06 Million | $1.39 Billion | ▼ -5.5% |
| 2015 | 0.09x | $104.88 Million | $1.20 Billion | — |